588729-99-1

Basic information

• Product Name: 2-Chloro-3-amino-5-bromopyridine
• Synonyms: 5-BROMO-2-CHLORO-3-PYRIDINAMINE;5-BROMO-2-CHLORO-PYRIDIN-3-YLAMINE;5-BROMO-2-CHLOROPYRIDIN-3-AMINE;3-AMINO-5-BROMO-2-CHLOROPYRIDINE;2-Chloro-3-amino-5-bromopyridine;3-Amino-5-bromo-2-chloropyridi;3-Amino-5-Bromo-2-Chloropyrid ;6-(4-fluorophenyl)-2-hydroxynicotinonitrile
• CAS NO: 588729-99-1
• Molecular Formula: C₅H₄BrClN₂
• Molecular Weight: 207.46
• EINECS: -0
• Product Categories: Pyridines ,Halogenated Heterocycles;blocks;Bromides;Pyridines;Pyridine;Pyridines, Pyrimidines, Purines and Pteredines;pharmacetical;Pyridine series;Amines
• Mol File: 588729-99-1.mol

Chemical Properties

• Melting Point: 129-132℃
• Boiling Point: 296.778 °C at 760 mmHg
• Flash Point: 133.287 °C
• Appearance: /
• Density: 1.835 g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.648
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• PKA: 0.03±0.10(Predicted)
• CAS DataBase Reference: 2-Chloro-3-amino-5-bromopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Chloro-3-amino-5-bromopyridine(588729-99-1)
• EPA Substance Registry System: 2-Chloro-3-amino-5-bromopyridine(588729-99-1)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25-37/38-41-22
• Safety Statements: 26-39-45
• RIDADR: 2811
• WGK Germany: 3
• HazardClass: IRRITANT
• PackingGroup: Ⅲ
• Hazardous Substances Data: 588729-99-1(Hazardous Substances Data)

Usage

Chemical Properties

Colorless solid

InChI:InChI=1/C5H4BrClN2/c6-3-1-4(8)5(7)9-2-3/h1-2H,8H2

Upstream product

• 90902-84-4 2,5-dibromopyridin-3-ylamine 
• 67443-38-3 5-bromo-2-chloro-3-nitropyridine 
• 15862-37-0 2,5-dibromo-3-nitro-pyridine 
• 7647-01-0 hydrogenchloride 
• 15862-34-7 5-bromo-3-nitro-2-pyridone 
• 15862-34-7 5-bromo-3-nitro-1H-pyridin-2-one 
• 1083326-15-1 2-amino-5-bromo-N,N-dimethylpyridine-3-sulfonamide 
• 73183-34-3 bis(pinacol)diborane 
• 6945-68-2 5-bromo-3-nitro-pyridin-2-ylamine 

Downstream Products

• 97966-00-2 5-bromo-2,3-dichloropyridine 
• 1073354-96-7 2-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-3-amine 
• 1083326-17-3 N-(5-bromo-2-chloropyridin-3-yl)benzenesulfonamide 
• 1112982-79-2 N-(5-bromo-2-chloro-3-pyridinyl)-4-fluoro-N-((4-fluorophenyl)sulfonyl)benzenesulfonamide 
• 1112982-81-6 N-(5-bromo-2-chloropyridin-3-yl)-4-methoxybenzenesulfonamide 
• 1162680-94-5 N-(5-bromo-2-chloropyridin-3-yl)-4-methylbenzenesulfonamide 
• 1162680-92-3 N-(5-bromo-2-chloropyridin-3-yl)-2-chloro-4-fluorobenzenesulfonamide 
• 1112983-26-2 N-(5-bromo-2-chloropyridin-3-yl)-3-(difluoromethoxy)benzenesulfonamide 
• 887309-87-7 N-(5-bromo-2-chloro-pyridine-3-yl)-4-fluorobenzenesulfonamide 
• 1198803-13-2 N-(5-bromo-2-chloro-3-pyridinyl)-2,5-dimethylbenzenesulfonamide 
• 1086065-27-1 N-(5-bromo-2-chloro-3-pyridinyl)-5-fluoro-2-methylbenzenesulfonamide 
• 1086065-23-7 N-(5-bromo-2-chloro-3-pyridinyl)-2-methylbenzenesulfonamide 
• 193888-15-2 tert-butyl 5-bromo-2-chloropyridin-3-ylcarbamate 
• 1310049-07-0 N-(2-chloro-5-bromopyridin-3-yl)-2-fluorobenzenesulfonamide 

Relevant articles and documents

SUBSTITUTED 2-AMINOPYRIDINE PROTEIN KINASE INHIBITOR

Disclosed are a 2-aminopyridine derivative having protein kinase inhibition activity, a preparation method and a pharmaceutical composition thereof Also disclosed are uses of the compounds and the pharmaceutical compositions thereof in the preparation of drugs for treating and/or preventing protein kinase-related diseases.

Synthesis and anticancer activity evaluation of a series of [1,2,4] triazolo[1,5-a]pyridinylpyridines in vitro and in vivo

A series of [1,2,4]triazolo[1,5-a]pyridinylpyridines were synthesized and characterized. Their anti-proliferative activities in vitro were evaluated by MTT against three human cancer cell lines including HCT-116, U-87 MG and MCF-7 cell lines. The SAR of target compounds was preliminarily discussed. The compounds 1c and 2d with potent antiproliferative activities were tested for their effects on the AKT and p-AKT473. The anticancer effect of 1c was evaluated in mice bearing sarcoma S-180 model. The results suggest that the title compounds are potent anticancer agents.

NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND USE THEREOF

The invention provides novel substituted pyridopyrimidines represented by Formula I or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof, and a composition comprising these compounds. The compounds provided can be used as inhibitors of the phosphoinositide 3′ OH kinase family (PI3K) for the treatment of inflammatory diseases, cancer, cardiovascular diseases, allergy, asthma and autoimmune disorders.

Substituted Benzo-Pyrido-Triazolo-Diazepine Compounds

The present invention relates to substituted benzo-pyrido-triazolo-diazepine compounds and methods of synthesizing these compounds. The present invention also relates to pharmaceutical compositions containing substituted benzo-pyrido-triazolo-diazepine compounds and methods of treating cell proliferative disorders, such as cancer, by administering these compounds or pharmaceutical compositions to subjects in need thereof.

QUINOXALINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PI3 kinases using quinoxaline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinoxaline derivatives.

QUINAZOLINE DERIVATIVES AS PI3 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of P13 kinases using quinazoline derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of quinazoline derivatives.

NAPHTHYRIDINE, DERIVATIVES AS P13 KINASE INHIBITORS

Invented is a method of inhibiting the activity/function of PB kinases using naphthyridine derivatives. Also invented is a method of treating one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries by the administration of naphthyridine derivatives.

THIAZOLE DERIVATIVES AND THEIR USE AS ANTI-TUMOUR AGENTS

The invention concerns thiazole derivatives of Formula (I) or pharmaceutically-acceptable salts thereof, wherein each of R, Ring A, m, R1, R2 and R3 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

5-HETEROARYL THIAZOLES AND THEIR USE AS P13K INHIBITORS

The invention provides thiazole derivatives of formula (I), or pharmaceutically acceptable salts thereof in which Ring A, R1, R2 and R3 are as defined in the specification; a processes for their preparation; pharmaceutical compositions containing them; and their use in therapy, for example in the treatment of disease mediated by a PI3K enzyme and/or a mTOR kinase.

Oxidative cyclization of N-methyl- and N-benzoylpyridylthioureas. Preparation of new thiazolo[4,5-b] and [5,4-b]pyridine derivatives

Cyclization of N-methyl- and N-benzoylpyridylthioureas, prepared from the corresponding aminopyridines, has been realized using various conditions. With bromine in acetic acid or potassium ferricyanide, the cyclization occurred on the nitrogen of the pyridine ring and pyridinium salts or 1,2,4-thiadiazolo[2,3-a]pyridylidene systems were obtained. On the other hand, treatment of the thioureas with sodium methoxide in N-methylpyrrolidinone (NMP) led to formation of thiazolo[4,5-b] and [5,4-b]pyridines, which are interesting targets for biological evaluation.